8 minute read
Dec. 4, 2023
PF-9363: A First-in-Class KAT6A/B Epigenetic “Writer” Inhibitor for Breast Cancer
PF-9363
oral selective KAT6A/B inhibitor related PF-07248144 in Ph. I for ER+ HER2 breast cancer from HTS of 250k compound library Cell Chem. Biol., August 2023 Pfizer, CA/ Cancer Therapeutics, AU
Author:
Reviewer:
Loading...
